End of an era in antibiotic blockbusters as FDA approves Levaquin generics
This article was originally published in Scrip
The US Food and Drug Administration has approved the first generic versions of Johnson & Johnson’s blockbuster antibacterial drug Levaquin (levofloxacin). Twelve companies, including generic heavyweights Mylan and Teva Pharmaceutical Industries, had applied to market generic versions of the drug in the lucrative US market.
You may also be interested in...
On 27 May, the US Food and Drug Administration (FDA) approved San Diego-based Optimer Pharmaceuticals' Dificid (fidaxomicin), a new antibiotic for the treatment of Clostridium difficile-associated diarrhoea (CDAD).